- Home
- TIXT vs EVO Comparison
TIXT vs EVO Comparison
Compare TIXT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- EVO
- Stock Information
- Founded
- TIXT 2005
- EVO 1993
- Country
- TIXT Canada
- EVO Germany
- Employees
- TIXT N/A
- EVO N/A
- Industry
- TIXT EDP Services
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- TIXT Technology
- EVO Health Care
- Exchange
- TIXT Nasdaq
- EVO Nasdaq
- Market Cap
- TIXT 1.3B
- EVO 1.2B
- IPO Year
- TIXT 2021
- EVO 2021
- Fundamental
- Price
- TIXT $4.48
- EVO $3.47
- Analyst Decision
- TIXT Hold
- EVO Buy
- Analyst Count
- TIXT 6
- EVO 2
- Target Price
- TIXT $3.90
- EVO $5.40
- AVG Volume (30 Days)
- TIXT 2.3M
- EVO 45.6K
- Earning Date
- TIXT 11-07-2025
- EVO 11-05-2025
- Dividend Yield
- TIXT N/A
- EVO N/A
- EPS Growth
- TIXT N/A
- EVO N/A
- EPS
- TIXT N/A
- EVO N/A
- Revenue
- TIXT $2,718,000,000.00
- EVO $912,894,891.00
- Revenue This Year
- TIXT $5.34
- EVO $0.43
- Revenue Next Year
- TIXT $3.07
- EVO $9.72
- P/E Ratio
- TIXT N/A
- EVO N/A
- Revenue Growth
- TIXT 2.03
- EVO N/A
- 52 Week Low
- TIXT $2.13
- EVO $2.84
- 52 Week High
- TIXT $4.60
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- TIXT 69.24
- EVO 41.34
- Support Level
- TIXT $3.77
- EVO $3.40
- Resistance Level
- TIXT $4.54
- EVO $3.55
- Average True Range (ATR)
- TIXT 0.06
- EVO 0.07
- MACD
- TIXT 0.04
- EVO 0.02
- Stochastic Oscillator
- TIXT 91.56
- EVO 42.31
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.